Alborn WE - Search Results

1

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G. Schmidt RJ, et al. Among authors: alborn we. Biochem Biophys Res Commun. 2008 Jun 13;370(4):634-40. doi: 10.1016/j.bbrc.2008.04.004. Epub 2008 Apr 10. Biochem Biophys Res Commun. 2008. PMID: 18406350

2

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ. Alborn WE, et al. Clin Chem. 2007 Oct;53(10):1814-9. doi: 10.1373/clinchem.2007.091280. Epub 2007 Aug 16. Clin Chem. 2007. PMID: 17702855

3

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Careskey HE, et al. Among authors: alborn we. J Lipid Res. 2008 Feb;49(2):394-8. doi: 10.1194/jlr.M700437-JLR200. Epub 2007 Nov 21. J Lipid Res. 2008. PMID: 18033751 Free article.

4

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

Troutt JS, Alborn WE, Cao G, Konrad RJ. Troutt JS, et al. Among authors: alborn we. J Lipid Res. 2010 Feb;51(2):345-51. doi: 10.1194/jlr.M000620. Epub 2009 Sep 8. J Lipid Res. 2010. PMID: 19738285 Free PMC article.

5

Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum.

Alborn WE, Johnson MG, Prince MJ, Konrad RJ. Alborn WE, et al. Clin Chem. 2006 Mar;52(3):514-7. doi: 10.1373/clinchem.2005.061374. Clin Chem. 2006. PMID: 16510431

6

The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity.

Lee TN, Alborn WE, Knierman MD, Konrad RJ. Lee TN, et al. Among authors: alborn we. Biochem Pharmacol. 2006 Sep 14;72(6):710-8. doi: 10.1016/j.bcp.2006.06.005. Epub 2006 Jul 17. Biochem Pharmacol. 2006. PMID: 16844097

7

Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase.

Lee TN, Alborn WE, Knierman MD, Konrad RJ. Lee TN, et al. Among authors: alborn we. Biochem Biophys Res Commun. 2006 Dec 1;350(4):1038-43. doi: 10.1016/j.bbrc.2006.09.155. Epub 2006 Oct 6. Biochem Biophys Res Commun. 2006. PMID: 17045574

8

An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.

Troutt JS, Alborn WE, Mosior MK, Dai J, Murphy AT, Beyer TP, Zhang Y, Cao G, Konrad RJ. Troutt JS, et al. Among authors: alborn we. J Lipid Res. 2008 Mar;49(3):581-7. doi: 10.1194/jlr.M700385-JLR200. Epub 2007 Dec 3. J Lipid Res. 2008. PMID: 18056684 Free article.

9

The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.

O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. O'Brien PJ, et al. Among authors: alborn we. Clin Chem. 2005 Feb;51(2):351-9. doi: 10.1373/clinchem.2004.040824. Epub 2004 Nov 4. Clin Chem. 2005. PMID: 15528295

10

Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio.

Schultze AE, Alborn WE, Newton RK, Konrad RJ. Schultze AE, et al. Among authors: alborn we. J Lipid Res. 2005 Aug;46(8):1591-5. doi: 10.1194/jlr.C500010-JLR200. Epub 2005 May 16. J Lipid Res. 2005. PMID: 15897610 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters